Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Repayment of subsidiary indebtedness
Repayment of indebtedness owed by ILSL Holdings, Inc., a subsidiary of the company.
Capital expenditure for a subsidiary
Funding capital expenditure requirements at Indegene, Inc., a subsidiary of the company.
General corporate purposes and inorganic growth
General corporate purposes, including funding potential inorganic growth opportunities.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
No peer comparisons added yet.
Indegene Limited is a Bengaluru-headquartered company, founded in 1998, that provides digital-led commercialization services to the life sciences and pharmaceutical industry. Its offerings span drug development support, clinical trial assistance, regulatory submissions, pharmacovigilance, complaints management, and sales and marketing support for biopharmaceutical companies, combining domain expertise in life sciences with digital and data-analytics capabilities. As of December 2023 the company reported around 5,181 employees globally, with the majority based in India and smaller teams in North America, Europe and China, and it served roughly 65 active clients drawn from across the pharmaceutical and life sciences sector. The company does not have a single identifiable individual promoter; it is professionally managed and was, at the time of its IPO, backed by private equity investors including Carlyle-affiliated entities. Operating in a segment tied closely to pharmaceutical research and development and commercialization budgets, the company's revenue and profitability have grown over recent years, reflecting increased outsourcing of digital and commercialization functions by biopharma companies, though its performance remains linked to the spending patterns of a concentrated set of large life-sciences clients.
No anchor investors added yet.
Source: RHP • Analysis provided for informational purposes
Last Updated: 14 July 2026, 5:30 AM
Deep life-sciences domain expertise
Decades of specialized experience since 1998 serving biopharmaceutical clients across drug development, regulatory and commercialization functions.
Broad, blue-chip client base
The company served around 65 active pharmaceutical and life-sciences clients as of December 2023, reflecting a diversified base of large industry customers.
Strong profitability and returns
The business has posted healthy profit margins and return on equity, supported by a technology and analytics-driven service model.
Established global delivery footprint
A workforce of over 5,000 employees spread across India, North America, Europe and China supports delivery close to major life-sciences markets.
No single controlling promoter
The company is professionally managed and backed by private equity investors rather than a founder-promoter, which can mean less long-term insider alignment and a future overhang as financial sponsors reduce their stakes.
Client concentration in a narrow industry
Reliance on a relatively concentrated set of large biopharmaceutical clients exposes the business to their outsourcing budgets and vendor decisions.
Rising leverage alongside growth
Borrowings have increased as the company has scaled, which could pressure margins if growth slows or funding costs rise.
Indegene Limited
Aspen Block, G4, 3rd Floor, Manyata Embassy Business Park, Outer Ring Road, Nagawara, Bengaluru 560045, Karnataka, India
View on Maps →MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Sector and regulatory dependence
Demand is tied to pharmaceutical research, regulatory and commercialization cycles, which can shift with industry spending patterns and regulatory change.